TNFRSF4 and cancer: Simultaneous administration of anti-PD-1 antibody and anti-OX40 antibody could reduce the antitumor effect of the anti-OX40 antibody; in contrast, administration of anti-PD-1 antibody after anti-OX40 antibody could produce synergistic antitumor effects in animal models, indicating the importance of the administered sequence of anti-PD-1 antibody in combined cancer immunotherapy (9).